Đang chuẩn bị liên kết để tải về tài liệu:
CPA-7 influences immune profile and elicits anti-prostate cancer effects by inhibiting activated STAT3

Không đóng trình duyệt đến khi xuất hiện nút TẢI XUỐNG Tải xuống

Platinum-based chemotherapy is emerging as the first line of treatment for castration resistant prostate cancer. Among the family of platinum (IV)-based compounds, a member known as CPA-7 inhibits the growth of multiple cancer cell lines. However, how and to what extent CPA-7 elicits its anti-prostate cancer effects in vivo is largely unknown. |